| Literature DB >> 29578032 |
Matthew E Tracy1, Vesna Tesic1, Tamara Timic Stamenic1, Srdjan M Joksimovic1, Nicolas Busquet2, Vesna Jevtovic-Todorovic1, Slobodan M Todorovic3.
Abstract
Recent data have implicated voltage-gated calcium channels in the regulation of the excitability of neurons within the mesolimbic reward system. While the attention of most research has centered on high voltage L-type calcium channel activity, the presence and role of the low voltage-gated T-type calcium channel (T-channels) has not been well explored. Hence, we investigated T-channel properties in the neurons of the ventral tegmental area (VTA) utilizing wild-type (WT) rats and mice, CaV3.1 knock-out (KO) mice, and TH-eGFP knock-in (KI) rats in acute horizontal brain slices of adolescent animals. In voltage-clamp experiments, we first assessed T-channel activity in WT rats with characteristic properties of voltage-dependent activation and inactivation, as well as characteristic crisscrossing patterns of macroscopic current kinetics. T-current kinetics were similar in WT mice and WT rats but T-currents were abolished in CaV3.1 KO mice. In ensuing current-clamp experiments, we observed the presence of hyperpolarization-induced rebound burst firing in a subset of neurons in WT rats, as well as dopaminergic and non-dopaminergic neurons in TH-eGFP KI rats. Following the application of a pan-selective T-channel blocker TTA-P2, rebound bursting was significantly inhibited in all tested cells. In a behavioral assessment, the acute locomotor increase induced by a MK-801 (Dizocilpine) injection in WT mice was abolished in CaV3.1 KO mice, suggesting a tangible role for 3.1 T-type channels in drug response. We conclude that pharmacological targeting of CaV3.1 isoform of T-channels may be a novel approach for the treatment of disorders of mesolimbic reward system. Published by Elsevier Ltd.Entities:
Keywords: Burst firing; Dopamine; Low-voltage-activated; Rebound spiking; T-type calcium channel; TTA-P2; Ventral tegmental area
Mesh:
Substances:
Year: 2018 PMID: 29578032 PMCID: PMC5975125 DOI: 10.1016/j.neuropharm.2018.03.028
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250